GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (FRA:2H51) » Definitions » Current Deferred Revenue

Ocugen (FRA:2H51) Current Deferred Revenue : €7.12 Mil (As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is Ocugen Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Ocugen's current deferred revenue for the quarter that ended in Mar. 2025 was €7.12 Mil.

Ocugen Current Deferred Revenue Historical Data

The historical data trend for Ocugen's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocugen Current Deferred Revenue Chart

Ocugen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 10.59 9.65 7.99

Ocugen Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.84 8.16 7.32 7.99 7.12

Ocugen Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Ocugen's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocugen Business Description

Industry
Traded in Other Exchanges
Address
11 Great Valley Parkway, Malvern, PA, USA, 19355
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Ocugen Headlines

No Headlines